Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17654219 | 0.80 | — | — | |
| SCHEMBL8216857 | 0.78 | DRD2 (0.40) | DRD2DRD3HTR1A | |
| SCHEMBL3763673 | 0.76 | DRD2 (0.37) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL1607384 | 0.76 | HRH1 (0.35) | — | |
| SCHEMBL1607566 | 0.74 | HRH1 (0.32) | — | |
| SCHEMBL189493 | 0.74 | DRD2 (0.45) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL1698318 | 0.73 | — | — | |
| SCHEMBL3996326 | 0.73 | DRD2 (0.37) | DRD2DRD3HTR1AHTR2A | |
| SCHEMBL15415320 | 0.73 | DRD2 (0.38) | DRD2DRD3 | |
| SCHEMBL2894209 | 0.72 | HTR3A (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-10-19 | — | — | US | claimed |
| EP-4251615-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-10-04 | — | — | EP | claimed |
| CN-116406362-A | Spiro [3.3] heptane derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-07-07 | — | — | CN | claimed |
| WO-2022112188-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-02 | — | — | WO | claimed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | claimed |
| WO-2018052967-A1 | SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA, INC. (US) | 2018-03-22 | — | — | WO | claimed |
| EP-3294729-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | claimed |
| US-20170273961-A1 | NOVEL IMINONITRILE DERIVATIVES | CURADEV PHARMA, PVT. LTD. (IN) | 2017-09-28 | — | — | US | claimed |
| EP-3183235-A1 | NOVEL IMINONITRILE DERIVATIVES | Curadev Pharma Pvt. Ltd. (IN) | 2017-06-28 | — | — | EP | claimed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | claimed |
| WO-2011161009-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-29 | — | — | WO | claimed |
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | claimed |
| WO-2011128251-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | claimed |
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2011-10-20 | — | — | US | claimed |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | NOVARTIS AG | 2010-12-16 | — | — | US | claimed |
| US-7115654-B2 | Caspase-1 inhibitors and methods for their use | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | claimed |
| US-20040229917-A1 | Imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | claimed |
| US-20040048895-A1 | Caspase-1 inhibitors and methods for their use | SUNESIS PHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | claimed |
| WO-2003103599-A2 | CASPASE-1 INHIBITORS AND METHODS FOR THEIR USE | SUNESIS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | claimed |
| US-6646010-B2 | Enzyme inhibitors such as N(3-benzyloxycarbonylamino-2-hydroxy -4-phenylbutyl)-N-isoamylamine, used for prophylaxis of viral diseases and infections; lymphadenopathy associated virus | G. D. SEARLE & CO. | 2003-11-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331715-A1 | SPIRO[3.3]HEPTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR1I3, NR1H4 | DRD2 3044/4885DRD3 1248/4885HTR1A 3105/4885 |
| US-20040048895-A1 | Caspase-1 inhibitors and methods for their use | CASP1, CASP2, CASP9 | DRD2 3953/4885DRD3 3001/4885HTR1A 646/4885 |
| US-20170273961-A1 | NOVEL IMINONITRILE DERIVATIVES | UGT1A4, XDH, CYP4B1 | DRD2 665/4885DRD3 840/4885HTR1A 396/4885 |
| US-20040229917-A1 | Imidazole derivatives | GRIK4, GRIA4, GRIK5 | DRD2 111/4885DRD3 195/4885HTR1A 32/4885 |
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | QDPR, PRMT3, PRMT1 | DRD2 126/4885DRD3 82/4885HTR1A 116/4885 |
| US-20100317657-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES | PRKCA, CSNK1A1, ABL1 | DRD2 4746/4885DRD3 4329/4885HTR1A 2718/4885 |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | DRD2 4118/4885DRD3 4136/4885HTR1A 3478/4885 |
| US-20110313151-A1 | ANELLATED PYRIDINE COMPOUNDS | ADORA3, ADORA2A, HTR3A | DRD2 78/4885DRD3 84/4885HTR1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.